Вопросы и обращения – Bioequivalence.design

Bioequivalence.design | PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Ваше имя (обязательно)

Ваш e-mail (обязательно)

Организация

Ваш телефон

Тема

Сообщение

Найти:

Свежие записи

Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0
ClinicalTrialUtilities: обзор
Подборка полезной литературы – часть 2

Галерея

Guidances (Drugs)
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-28 By FDA
Coronavirus Aid, Relief, and Economic Security Act (CARES Act) Drug Shortage Mitigation Efforts
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-28 By FDA
FDA Drug Competition Action Plan
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-28 By FDA
Activities Report of the Generic Drug Program | FDARA Title VIII Sections 807 and 805
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-28 By FDA
Activities Report of the Generic Drugs Program (FY 2021) – FDARA Title VIII Section 807 and 805
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-28 By FDA
Meeting Materials, Vaccines and Related Biological Products Advisory Committee
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-01-28 By FDA
Vaccines and Related Biological Products Advisory Committee March 3, 2022 Meeting Announcement - 03/03/2022
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-01-28 By FDA
CDERLearn Training and Education
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-28 By FDA
2022 Meeting Materials, Vaccines and Related Biological Products Advisory Committee
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-01-28 By FDA
AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Polymyxin B for Injection USP, 500,000 Unit per Vial, Due to the Presence of Particulate Matter
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-28 By FDA
Human medicines European public assessment report (EPAR): Aubagio, teriflunomide, Multiple Sclerosis, Date of authorisation: 26/08/2013, Revision: 22, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-01-28
Guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials - Revision 2
Source: EMA - Scientific guidelines (human and veterinary) Published on 2022-01-28
Human medicines European public assessment report (EPAR): Simponi, golimumab, Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Arthritis, Rheumatoid, Date of authorisation: 01/10/2009, Revision: 43, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-01-28
Postmarket Requirements and Commitments
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-28 By FDA
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), COVID-19 virus infection, Date of authorisation: 20/12/2021, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-01-28

Предыдущие записи

Тема: Scaffold от Danny Cooper.